ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
06 févr. 2024 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 06, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society
23 janv. 2024 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
28 août 2023 07h00 HE
|
ONL Therapeutics
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct to standard-of-care surgery Topline data readout...
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
12 avr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
11 avr. 2023 07h00 HE
|
ONL Therapeutics
Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited...
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
08 mars 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
13 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
02 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
01 févr. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
26 janv. 2023 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...